Terence Flynn
Stock Analyst at Morgan Stanley
(4.29)
# 390
Out of 5,182 analysts
248
Total ratings
57.69%
Success rate
13.71%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $596 → $612 | $427.33 | +43.21% | 5 | Apr 10, 2026 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $471 → $519 | $569.44 | -8.86% | 12 | Apr 10, 2026 | |
| RPRX Royalty Pharma | Maintains: Overweight | $61 → $63 | $49.80 | +26.51% | 14 | Apr 10, 2026 | |
| PFE Pfizer | Maintains: Equal-Weight | $27 → $28 | $27.02 | +3.63% | 22 | Apr 10, 2026 | |
| JNJ Johnson & Johnson | Maintains: Overweight | $262 → $267 | $228.68 | +16.76% | 29 | Apr 10, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,313 → $1,327 | $874.40 | +51.76% | 25 | Apr 10, 2026 | |
| BNTX BioNTech SE | Maintains: Overweight | $125 → $126 | $101.07 | +24.67% | 7 | Apr 10, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $309 → $326 | $342.97 | -4.95% | 13 | Apr 10, 2026 | |
| ALMS Alumis | Maintains: Overweight | $33 → $38 | $24.90 | +52.61% | 4 | Mar 20, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $269 → $270 | $198.10 | +36.29% | 20 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $23 → $20 | $25.22 | -20.70% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $36 | $17.00 | +111.76% | 7 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $21 | $9.75 | +115.38% | 5 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $37 | $58.24 | -36.47% | 12 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $102 | $111.66 | -8.65% | 20 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $47.10 | +165.39% | 2 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $9 | $13.22 | -31.92% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $10.43 | +5.47% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $50.25 | -36.32% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $13.46 | -18.28% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.88 | +177.78% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $183.28 | +137.89% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $311.33 | - | 2 | Oct 2, 2017 |
Vertex Pharmaceuticals
Apr 10, 2026
Maintains: Overweight
Price Target: $596 → $612
Current: $427.33
Upside: +43.21%
United Therapeutics
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $471 → $519
Current: $569.44
Upside: -8.86%
Royalty Pharma
Apr 10, 2026
Maintains: Overweight
Price Target: $61 → $63
Current: $49.80
Upside: +26.51%
Pfizer
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $27 → $28
Current: $27.02
Upside: +3.63%
Johnson & Johnson
Apr 10, 2026
Maintains: Overweight
Price Target: $262 → $267
Current: $228.68
Upside: +16.76%
Eli Lilly and Company
Apr 10, 2026
Maintains: Overweight
Price Target: $1,313 → $1,327
Current: $874.40
Upside: +51.76%
BioNTech SE
Apr 10, 2026
Maintains: Overweight
Price Target: $125 → $126
Current: $101.07
Upside: +24.67%
Amgen
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $309 → $326
Current: $342.97
Upside: -4.95%
Alumis
Mar 20, 2026
Maintains: Overweight
Price Target: $33 → $38
Current: $24.90
Upside: +52.61%
AbbVie
Feb 5, 2026
Maintains: Overweight
Price Target: $269 → $270
Current: $198.10
Upside: +36.29%
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $20
Current: $25.22
Upside: -20.70%
Jan 8, 2026
Upgrades: Overweight
Price Target: $15 → $36
Current: $17.00
Upside: +111.76%
Jan 6, 2026
Maintains: Overweight
Price Target: $26 → $21
Current: $9.75
Upside: +115.38%
Dec 12, 2025
Maintains: Underweight
Price Target: $36 → $37
Current: $58.24
Upside: -36.47%
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $100 → $102
Current: $111.66
Upside: -8.65%
Dec 12, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $47.10
Upside: +165.39%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $13.22
Upside: -31.92%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $10.43
Upside: +5.47%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $50.25
Upside: -36.32%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $13.46
Upside: -18.28%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.88
Upside: +177.78%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $183.28
Upside: +137.89%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $311.33
Upside: -